Drug Type Small molecule drug |
Synonyms WM 382, WM382 |
Target |
Action inhibitors |
Mechanism PfPMX inhibitors(Plasmodium falciparum plasmepsin X inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC29H36N4O4 |
InChIKeyZSZSSSHEMYULPX-FCHUYYIVSA-N |
CAS Registry2606990-92-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malaria, Falciparum | Preclinical | United States | 25 Oct 2019 | |
Malaria, Falciparum | Preclinical | United States | 25 Oct 2019 | |
Plasmodium knowlesi infection | Preclinical | United States | 25 Oct 2019 | |
Plasmodium knowlesi infection | Preclinical | United States | 25 Oct 2019 | |
Malaria | Preclinical | United States | - | |
Malaria | Preclinical | Australia | - |